Eversheds Sutherland Sweden advised Neola Medical on its SEK 20 million directed share issue, welcoming the company’s first institutional investors
April 15, 2025
Sweden
Sweden
Sweden
Neola Medical AB (publ) revolutionizes neonatal intensive care with Neola®—a medical device enabling continuous lung monitoring and real-time alerts for life-threatening complications using advanced technology to measure lung volume changes and oxygen concentration. The proceeds from the share issue will support ongoing clinical studies on preterm babies and preparations for the planned FDA application for Neola® in the U.S.
Eversheds Sutherland’s team consisted of Johan Engström, Kevin Holmkvist and Hanna Ullerholt. Handelsbanken acted as Sole Manager and Bookrunner in connection with the directed share issue.
The materials on the Eversheds Sutherland website are for general information purposes only and do not constitute legal advice. While reasonable care is taken to ensure accuracy, the materials may not reflect the most current legal developments. Eversheds Sutherland disclaims liability for actions taken based on the materials. Always consult a qualified lawyer for specific legal matters. To view the full disclaimer, see our Terms and Conditions or Disclaimer section in the footer.